1. To present results of a phase II study of pembrolizumab and ipilimumab following initial anti-PD1/L1 antibody
2. To review associated toxicities of immune checkpoint inhibitors and our current understanding of toxicity mechanisms.
3. To learn the role of tissue-resident memory T cells in immunotherapy response and their potential role as biomarker for immune-related adverse events.ng initial anti-PD1/L1 antib
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation